Tetrahydrocannabinol Thc
Tetrahydrocannabinol Thc - Related Videos
07:51
Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
0 Views •
2025
Δ9-tetrahydrocannabinol (THC) is the intoxicating constituent in cannabis and a controlled substance in the United States. This article outlines standard procedures for obtaining, storing, and administering THC to mice complying with current legal regulations and briefly introduces a method to assess basic pharmacodynamic effects of THC in rodents.
05:13
Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
0 Views •
Cited by 1 •
2025
As legislative restrictions change, resulting in increased accessibility of cannabinoid products, it is critically important to develop models to study the impact of these exposures, particularly during pregnancy. A preclinical model of moderate prenatal cannabinoid exposure through voluntary ingestion has been developed, enabling more in-depth investigations.
FAQs
THC activates CB1 and CB2 receptors, which are Gi/o protein-coupled receptors. Their signaling reduces neurotransmitter release and changes communication between neurons. This molecular pathway provides a pharmacological explanation for downstream changes in perception, mood, pain, appetite, and memory, linking receptor activity with observable effects.
The partial-agonist property identifies THC as a receptor activator whose effects depend on CB1 and CB2 signaling. This distinction helps pharmacologists interpret cannabinoid experiments, compare receptor-linked responses, and relate molecular activity to altered neural communication rather than treating cannabinoid exposure as a nonspecific process.
After absorption, the liver converts THC into both active and inactive metabolites. Active metabolites can contribute to the overall pharmacological response, while inactive metabolites do not produce the same activity. Metabolism therefore helps explain why the effects of a dose can vary in intensity and duration over time.
The route of administration changes how THC is absorbed and processed before its effects are evaluated. Inhaled and oral doses therefore differ in onset, duration, and intensity, partly because liver metabolism produces active and inactive metabolites. Pharmacological comparisons must account for both the delivery route and subsequent metabolic conversion.
THC is studied when researchers need to connect cannabinoid receptor signaling with potential therapeutic effects and adverse outcomes. Its pharmacology can inform investigations of changes in pain, appetite, mood, perception, and memory, while also supporting assessment of how cannabinoid-based medicines should be evaluated and regulated.
Studies can examine receptor-mediated changes in neural communication alongside effects on perception, mood, pain, appetite, and memory. They can also assess how absorption and liver metabolism influence response patterns. Together, these outcomes provide pharmacological context for therapeutic research, adverse-effect assessment, and regulation of cannabinoid-based medicines.